Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 17, 2017

Study Completion Date

December 15, 2017

Conditions
Autonomic Dysreflexia
Interventions
DRUG

BOTOX

"BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia."

Trial Locations (1)

V5Z 1M9

International Collaboration on Repair Discoveries (ICORD), Vancouver

All Listed Sponsors
collaborator

University of British Columbia

OTHER

collaborator

International Collaboration on Repair Discoveries

OTHER

collaborator

Vancouver Coastal Health

OTHER_GOV

lead

Rick Hansen Institute

OTHER

NCT02298660 - Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI | Biotech Hunter | Biotech Hunter